Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is representing investors of Quipt Home Medical Corp in an investigation regarding possible securities fraud [1] - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a misleading statement related to its acquisition offer [2] Group 2: Stock Performance - Following the news of Forager's request, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is conducting an investigation on behalf of investors of Quipt Home Medical Corp regarding possible securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information about the investigation [1] Group 2: Shareholder Actions - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a statement made on May 21, 2025, which they claim is false and misleading regarding an acquisition offer [3] - Following the press release from Forager, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [3]

Company Overview - Viemed Healthcare, Inc. is a national leader in respiratory care and technology-enabled home medical equipment services in the United States [2] - The company specializes in post-acute respiratory healthcare equipment and services, including non-invasive ventilators, sleep therapy, and staffing [2] - Viemed focuses on providing efficient and effective in-home treatment through clinical practitioners who deliver therapy, education, and counseling to patients [2] Event Announcement - Viemed will present at the East Coast IDEAS Investor Conference on June 11, 2025, at The Westin Times Square in New York, NY [1] - The presentation is scheduled to begin at 11:30 am ET and will be webcasted [1] - Access to the webcast is available through the conference host's website and Viemed's investor relations section [1] IDEAS Investor Conferences - The IDEAS Conferences aim to provide independent venues for quality companies to present their investment merits to investment professionals [3] - These conferences are sponsored by investors for the benefit of regional investment communities, with sponsors managing over $200 billion in assets [3] - The conferences are produced annually by Three Part Advisors, LLC [4]

Core Viewpoint - Quipt Home Medical Corp. has received an unsolicited non-binding proposal from Forager Capital Management to acquire 100% of its common shares at a price of $3.10 per share [1] Group 1: Proposal Details - The proposal is non-binding, conditional, and indicative, indicating that it is not a formal offer yet [1] - The Company has a Non-Disclosure and Standstill Agreement with Forager, which prohibits Forager from acquiring any equity securities or assets of Quipt for six months without prior approval from the Board [2] - The Board has not provided any prior written approval for the proposal, adhering to the terms of the Agreement [2] Group 2: Company Strategy and Operations - Quipt focuses on providing in-home monitoring and disease management services, particularly in respiratory care, and aims to expand its offerings for chronic disease management [4] - The primary business objective is to create shareholder value by offering a broader range of services to patients, thereby increasing annual revenue per patient [4] - The Company is committed to driving sustainable value for its shareholders and will consult with financial and legal advisors regarding the proposal [3]

Core Insights - Viemed Healthcare, Inc. reported strong financial results for Q1 2025, with net revenues of $59.1 million, a 17% increase from Q1 2024, and net income of $2.6 million, a 64% increase year-over-year [6][5][19] - The company has updated its full-year 2025 guidance, raising the lower end of its revenue and Adjusted EBITDA ranges due to improved performance across its business segments [5][3] - Viemed announced an agreement to acquire Lehan's Medical Equipment for $26 million, which is expected to enhance its service offerings in respiratory care and women's health [4][6] Financial Performance - Net revenues for Q1 2025 were $59.1 million, up from $50.6 million in Q1 2024, reflecting an increase of $8.5 million [6][19] - Adjusted EBITDA for Q1 2025 was $12.8 million, representing a 26% increase compared to Q1 2024 [6][19] - The company reported a net income of $2.6 million, or $0.06 per diluted share, compared to $1.6 million, or $0.04 per diluted share in the same quarter last year [6][19] Operational Highlights - The number of ventilator patients increased to 11,809, a 13% rise from March 31, 2024 [6][24] - The PAP therapy patient count rose to 22,899, marking a 46% increase year-over-year [6][24] - The sleep resupply patient count was 22,941, a 21% increase from the previous year [6][24] Guidance and Future Outlook - For the full year 2025, net revenue is expected to be in the range of $256 million to $265 million, up from the previous range of $254 million to $265 million [6][3] - Adjusted EBITDA for the year is projected to be between $55 million and $58 million, an increase from the prior range of $54 million to $58 million [6][3] - The anticipated acquisition of Lehan's Medical Equipment is not included in the current guidance but is expected to contribute positively once completed [4][6] Balance Sheet and Cash Flow - As of March 31, 2025, the company had a cash balance of $10.2 million and total assets of $178.1 million [6][17] - Long-term debt stood at $3.5 million, with $55 million available under existing credit facilities [6][17] - The company reported a net cash provided by operating activities of $2.9 million for Q1 2025 [20]

Company Overview - Viemed Healthcare, Inc. is a national leader in respiratory care and technology-enabled home medical equipment services in the United States [3] - The company specializes in post-acute respiratory healthcare equipment and services, including non-invasive ventilators, sleep therapy, and staffing [3] Upcoming Events - Viemed will host its First Quarter 2025 Earnings Conference Call on May 8, 2025, at 11:00 a.m. EDT [1] - Interested parties can participate via a toll-free number or an international dial-in, and a live audio webcast will be available [2] Contact Information - For further inquiries, contact Tripp Sullivan at SCR Partners, LLC or Todd Zehnder, Chief Operating Officer of Viemed Healthcare [4]

Financial Data and Key Metrics Changes - Fourth quarter revenue was effectively flat year-over-year but exceeded the high end of guidance by 3% [6][30] - Adjusted EBITDA for the fourth quarter contracted 2% year-over-year but was above guidance [7][36] - Free cash flow for the fourth quarter was $73 million, up 10% from the prior year [7][39] Business Line Data and Key Metrics Changes - Sleep Health revenue increased 3.4% year-over-year in Q4 [6][31] - Respiratory Health revenue increased 1% year-over-year in Q4 [6][33] - Diabetes Health revenue decreased 7.3% year-over-year in Q4, but showed sequential growth of $30.2 million over Q3 [6][34] - Wellness at Home revenue declined 0.8% year-over-year in Q4 [6][35] Market Data and Key Metrics Changes - For full year 2024, net revenue grew 1.9% to $3.26 billion, with notable growth in Sleep Health (4.5%) and Respiratory Health (6.0%) [30] - The company reported a net leverage ratio of 2.79 times at year-end 2024, down from 3.16 times at the end of 2023 [42] Company Strategy and Development Direction - The company is focusing on five areas: One Adapt initiative, AI and automation, clinical relevance, organic growth, and strengthening the balance sheet [8][24] - A new segment structure was implemented to enhance visibility and accountability [12][28] - The company aims to lead in innovation within the home health industry and improve patient experience through automation and AI [13][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to manage patient care and expand its role in healthcare [17][22] - The company anticipates 2025 to be a transition year for growth, with expectations for accelerated growth in 2026 and beyond [51] Other Important Information - The company reduced debt by $170 million in the past year, including $50 million in Q4 [24][42] - A multi-year extension of the capitated contract with Humana was announced [23] Q&A Session Summary Question: Can you talk more about the conversations with carriers over additional capitated arrangements? - Management confirmed ongoing discussions and a strong relationship with Humana, with positive performance reviews [55][56] Question: Can you discuss your working capital outlook and cash flow improvement? - Management indicated progress in working capital and expects stable or improved days sales outstanding (DSO) in 2025 [57][58] Question: What are your thoughts on the Diabetes business contribution to 2025 guidance? - Management noted stable revenue for pump supplies and cautious optimism for growth in the Diabetes segment [66][68] Question: Can you elaborate on the changes made in the Diabetes resupply outreach program? - Management highlighted the implementation of a new leadership team and improved patient outreach strategies [87][92] Question: How was the sales quota initiative received by the sales force? - Management reported a positive response from the sales team, which has improved forecasting and accountability [95][96] Question: Can you provide insights on the purchase versus rental revenue dynamics? - Management explained the impact of changes in reimbursement structures, particularly in the sleep business [102][103] Question: What is the expected impact of the 75/25 reimbursement model for 2025? - Management indicated a stable reimbursement environment with no significant changes expected [106][118]